LECT2通过激活Tie2/Akt/mTOR信号通路改善糖尿病继发的血-视网膜屏障损伤
本研究在糖尿病与非糖尿病眼组织及链脲佐菌素诱导糖尿病小鼠模型中,结合体外高糖处理的人视网膜微血管内皮细胞和脐静脉内皮细胞,发现LECT2及内皮间连接蛋白水平降低,重组LECT2可经Tie2/Akt/mTOR通路升高连接蛋白并改善屏障功能,玻璃体内注射rLECT2可逆转糖尿病所致连接破坏。
要点
- 糖尿病视网膜及高糖处理的内皮细胞中LECT2与内皮间连接蛋白水平降低。
- 重组LECT2(80 ng/mL)可减轻高糖所致内皮细胞屏障功能下降。
- 玻璃体内注射rLECT2(40 µg/mL,1 µL)可逆转糖尿病所致连接破坏。
核心结论
- rLECT2可通过激活Tie2/Akt/mTOR信号通路升高内皮间紧密连接蛋白水平,改善糖尿病继发的内层血-视网膜屏障损伤。
- LECT2可能是预防糖尿病视网膜病变进展的潜在靶点。
研究设计与样本
- 研究纳入20只糖尿病眼和22只非糖尿病眼,并建立链脲佐菌素诱导的糖尿病小鼠模型。
- 小鼠接受或不接受玻璃体内注射重组LECT2(40 µg/mL,1 µL)。
- 体外用0或30 mM葡萄糖处理融合的人视网膜微血管内皮细胞和人脐静脉内皮细胞0-72小时,并加或不加rLECT2(40-360 ng/mL)。
主要发现
- 在糖尿病的人和小鼠视网膜以及30 mM高糖处理的人视网膜微血管内皮细胞和人脐静脉内皮细胞中,LECT2和内皮间连接蛋白水平降低。
- rLECT2(80 ng/mL)显著减轻高糖诱导的内皮细胞屏障功能下降,并抑制人视网膜微血管内皮细胞和人脐静脉内皮细胞的迁移和管腔形成。
- rLECT2通过激活Tie2/Akt/mTOR信号通路升高内皮间连接蛋白水平。
- 玻璃体内注射rLECT2升高内皮间连接蛋白水平并逆转糖尿病诱导的连接破坏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Current treatments for diabetic retinopathy (DR) have considerable limitations, emphasizing the need for new therapeutic options. The effect of leukocyte cell-derived chemotaxin 2 (LECT2) on diabetes-induced blood-retinal barrier impairment and the possible underlying mechanism were investigated both in vivo and in vitro. METHODS: Twenty diabetic and 22 nondiabetic eyes were included in this study. Additionally, we established a streptozotocin-induced diabetic mouse model and observed vascular leakage in mice treated with or without recombinant LECT2 (rLECT2) intravitreal injection (40 µg/mL, 1 µL). The levels of LECT2 and interendothelial junction proteins (ZO1, VE-cadherin, and occludin) were analyzed by western blot and/or immunofluorescence. Endothelial junctions in mouse retinas were observed by transmission electron microscopy (TEM). Moreover, confluent human retinal microvascular endothelial cells (HRMECs) and human umbilical vein endothelial cells (HUVECs) were treated (0-72 hours) with glucose (0 or 30 mM) in the presence or absence of rLECT2 (40-360 ng/mL). After treatment, intact cell monolayers were monitored for permeability to 40-kD FITC-dextran. Interendothelial junction targets and Tie2/Akt/mTOR signaling pathway components were investigated by western blot. RESULTS: In diabetic human and mouse retinas and high-glucose (30 mM)-treated HRMECs and HUVECs, the levels of LECT2 and interendothelial junction proteins were decreased. rLECT2 treatment (80 ng/mL) significantly attenuated the hyperglycemia-induced reduction in endothelial cell barrier function and inhibited the migration and tube formation of HRMECs and HUVECs. In addition, rLECT2 increased the levels of interendothelial junction proteins via activation of the Tie2/Akt/mTOR signaling pathway. Furthermore, intravitreal rLECT2 injections increased the levels of interendothelial junction proteins and reversed diabetes-induced junction disruption. CONCLUSIONS: rLECT2 can increase the levels of interendothelial tight junction proteins through activation of the Tie2/Akt/mTOR signaling pathway and can ameliorate inner blood-retinal barrier impairment secondary to diabetes. LECT2 might be a potential target to prevent the progression of DR.
引用
- Qin YJ, Xiao K, Zhong Z, et al. LECT2 Ameliorates Blood-Retinal Barrier Impairment Secondary to Diabetes Via Activation of the Tie2/Akt/mTOR Signaling Pathway. Invest Ophthalmol Vis Sci. 2022. PMID: 35262733. doi:10.1167/iovs.63.3.7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。